Anebulo Pharmaceuticals Inc (ANEB) - Market Cap to Net Income

Anebulo Pharmaceuticals Inc - graphic logo of issuer ANEB

Anebulo Pharmaceuticals (ANEB) creates unique emergency aid products, ensuring stable demand and a prolonged period of monopoly income. The business relies on a narrow niche of cannabinoid neutralization, where the primary risks are associated with a limited market. This chart of PE ratio changes reflects -1.80. The company is currently completing final trials of a first-of-its-kind antidote, focusing on a breakthrough release.

anebulo.com (ANEB): Price to Earnings Ratio from 07/04/2022 to 03/07/2026

Comprehensive metric breakdowns and analytics for Anebulo Pharma (ANEB)

Comprehensive company analysis:Anebulo Pharmaceuticals, Inc. ANEB
Signature product of Anebulo

To assess the fundamental value of an asset, an investor compares market capitalization with annual net profit, determining the investment payback period via the P/E ratio. By analyzing the P/E ratio trend, one can identify whether Anebulo Pharmaceuticals (ANEB) is overvalued or undervalued, given that the high R&D costs associated with developing the Anebound antidote often outpace the current financial results of the biopharmaceutical sector.